###begin article-title 0
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
Hereditary cancers account for 5-10% of cancers. In this study BRCA1, BRCA2 and CHEK2*(1100delC) were analyzed for mutations in 91 HBOC/HBC/HOC families and early onset breast and early onset ovarian cancer cases.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
PCR-DHPLC was used for mutation screening followed by DNA sequencing for identification and confirmation of mutations. Kaplan-Meier survival probabilities were computed for five-year survival data on Breast and Ovarian cancer cases separately, and differences were tested using the Log-rank test.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Fifteen (16%) pathogenic mutations (12 in BRCA1 and 3 in BRCA2), of which six were novel BRCA1 mutations were identified. None of the cases showed CHEK2*1100delC mutation. Many reported polymorphisms in the exonic and intronic regions of BRCA1 and BRCA2 were also seen. The mutation status and the polymorphisms were analyzed for association with the clinico-pathological features like age, stage, grade, histology, disease status, survival (overall and disease free) and with prognostic molecular markers (ER, PR, c-erbB2 and p53).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
The stage of the disease at diagnosis was the only statistically significant (p < 0.0035) prognostic parameter. The mutation frequency and the polymorphisms were similar to reports on other ethnic populations. The lack of association between the clinico-pathological variables, mutation status and the disease status is likely to be due to the small numbers.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 46 51 <span type="species:ncbi:9606">women</span>
###xml 439 444 <span type="species:ncbi:9606">child</span>
Breast cancer is the most common cancer among women in Chennai with the crude incidence rate (CIR) being 30.1/100,000 in the Madras Metropolitan Tumor Registry (MMTR). A significant increasing trend in the incidence of breast cancer was seen during 1982-2005 with an average annual increase of 0.72 per 100,000 [1]. The trend of rising incidence rate is likely to continue due to further changes in life style factors such as age of first child birth and dietary habits [2].
###end p 11
###begin p 12
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 445 450 445 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 512 517 512 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 518 524 518 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 597 603 597 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 607 613 607 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 730 736 730 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 740 746 740 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 791 792 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 850 856 850 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1047 1053 1047 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1072 1073 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
BRCA1 and BRCA2 genes had been identified by linkage analysis and positional cloning on large breast cancer families in the early 1990's [3,4]. This has improved the understanding of the molecular genetics of the hereditary breast and ovarian cancer thus providing scope for better management in these patients and in offering predictive testing, aggressive screening and preventive strategies to the unaffected carriers in the same family. The CHEK2*1100delC mutation confers a low risk of breast cancer in non-BRCA1/BRCA2 mutation carriers [5]. The average cumulative risk of breast cancer in a BRCA1 and BRCA2 mutation carrier is 65% and 45% by the age of 70 years, respectively. For ovarian cancer the risk is 39% and 11%, in BRCA1 and BRCA2 mutation carriers by 70 years, respectively [6]. Slightly elevated risk of colon and prostate cancer in BRCA1 mutation carriers and increased risk of other malignancies including pancreatic, stomach and head and neck cancers and a large increase in the relative risk for male breast cancer is seen in BRCA2 mutation carriers [7,8].
###end p 12
###begin p 13
###xml 17 75 17 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53, ATM, SKT11, PTEN, PTCH MLH1, MSH2, PMS1, PMS2, MSH6 </italic>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 272 293 272 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2, TNRC9, MAP3K1 </italic>
###xml 297 302 297 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LSP1 </italic>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Other genes like TP53, ATM, SKT11, PTEN, PTCH MLH1, MSH2, PMS1, PMS2, MSH6 have been associated with increased risk of breast and ovarian cancer as part of other cancer syndromes [9]. Recently genome wide association study identified four plausible causative genes namely FGFR2, TNRC9, MAP3K1 and LSP1 that confer moderate susceptibility to breast cancer [10].
###end p 13
###begin p 14
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 534 540 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 656 662 656 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 704 710 704 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 867 872 867 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 874 880 874 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 884 889 884 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 984 989 984 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 991 997 991 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1001 1006 1001 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
Generally, hereditary breast cancers are earlier in onset and have a higher prevalence of bilateral breast cancers. Breast tumors from BRCA1- carriers are more likely to be highly proliferative; poorly differentiated (grade III); more likely to have a medullary or atypical medullary-like appearance with high degree of lymphocyte infiltration; and show excess of continuous pushing margins [11]. Moreover these tumors are more often ER, PR and c-erbB2 negative and frequently show p53 alterations [12]. Lakhani and Bell et al report BRCA2 tumors to be of higher grade than the sporadic group, but this was not confirmed by Eelora et al, 2005 [13-15]. The BRCA2 tumors are likely to be ER positive [16]. BRCA1 mutation carriers have an earlier onset of ovarian cancer that is histologically high-grade serous adenocarcinoma [17]. We had earlier published the data of BRCA1, BRCA2 and CHEK2*1100delC mutation status in 22 cases [18]. Here, we report the clinico-pathological features, BRCA1, BRCA2 and CHEK2*1100delC mutation status and their correlation with prognostic markers in 91 cases.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Materials
###end title 16
###begin p 17
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 123 129 123 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1448 1456 <span type="species:ncbi:9606">patients</span>
###xml 1523 1531 <span type="species:ncbi:9606">patients</span>
Ninety-one eligible cases including the 22 published that fulfilled the criteria for gene testing were screened for BRCA1, BRCA2 and CHEK2*1100delC mutations [18]. The criteria were as follows: Early onset of breast cancer (</=35 years of age) or ovarian cancer (</=40 years of age); Two cases of breast cancer diagnosed under the age of 50 years in a family (first and second degree relatives); Three or more cases of breast cancer diagnosed at any age; Presence of breast and ovarian cancer in the family or in the same individual; Male breast cancer with a relative (of either sex) with breast cancer; Family history of Prostate or pancreatic or colorectal cancer or sarcomas, with breast cancer in the family. The study includes 65 unilateral, 6 bilateral breast cancer cases, 14 ovarian cancer cases, 3 cases with both breast and ovarian cancer in the same individual without any family history of cancer, 2 cases each with family history of breast cancer and soft tissue sarcoma and 1 case of prostate cancer with family history of prostate and breast cancer. Of the 91 cases, 54 were with Family history (including 35 Hereditary Breast Cancer families, 15 Hereditary Breast & Ovarian Cancer families, 3 Hereditary Ovarian Cancer families and 1 with family history of Prostate and breast cancer). There were 31 early onset breast cancer (</= 35 yrs) and 3 early onset ovarian cancer (</= 40 yrs) cases without family history of cancer. Three patients had breast and ovarian cancers, without a family history. All the patients provided their informed consent for the study, which was cleared by the Institutional Ethical committee.
###end p 17
###begin title 18
Methods
###end title 18
###begin title 19
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC
###end title 19
###begin p 20
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
The sample collection, DNA isolation, PCR-DHPLC and sequencing were carried out as previously described [18].
###end p 20
###begin title 21
Bioinformatics Analysis
###end title 21
###begin p 22
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
The secondary structure and the tertiary structure of the normal CHEK2 gene sequence and the two missense variants were predicted by submitting the sequences to Chou Fasman secondary structure prediction site and at ExPaSy server for tertiary structure prediction using Swiss model [19-22].
###end p 22
###begin title 23
Immunohistochemistry
###end title 23
###begin p 24
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 277 283 <span type="species:ncbi:9986">rabbit</span>
###xml 289 294 <span type="species:ncbi:10090">mouse</span>
###xml 318 323 <span type="species:ncbi:9823">swine</span>
###xml 329 335 <span type="species:ncbi:9986">rabbit</span>
IHC was done for ER, PR, p53 and c-erbB2 expression studies on available breast cancer cases. IHC was performed as per the standard methodology using primary antibodies; clone ID5 (ER), clone PgR636 (PR), clone HER2/neu (c-erbB2), and clone DO7 (p53) and secondary antibodies; rabbit anti mouse for ER, PR and p53 and swine anti rabbit for c-erbB2 from Dako [23-26]. The antibodies were used at a dilution of 1:35 for ER and PR (Dako pharma), 1:350 for HER2/neu (Dako pharma) and 1:200 (Biogenex) or 1:50 (Dako pharma) for p53. Positive (known positives for each of the markers) and negative controls (omission of primary antibody) were included in each run. The scoring was done as described previously [23-26].
###end p 24
###begin title 25
Statistical Analysis
###end title 25
###begin p 26
###xml 374 380 374 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Chi-square test of independence was used for testing the statistical significance of association between the variables like age, stage, grade and histological type with disease status (i.e. disease free or disease present) and between clinico-pathological features and with each of the prognostic markers like ER, PR, c-erbB2 and p53 status for the breast cancer cases. The BRCA1 and BRCA2 mutation status i.e. mutation positivity or negativity were tested for statistical association with disease status and prognostic molecular markers. Yates correction was made wherever indicated. Fisher's exact probability test was employed to deal with small frequencies. Kaplan-Meier survival probabilities were computed for five-year survival data on Breast and Ovarian cancer cases separately, and differences were tested using the Log-rank test. All the statistical analyses were performed using Stata version 10.0 software.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
BRCA1 and BRCA2 analysis
###end title 28
###begin p 29
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Fifteen out of the 91 (16%) samples analyzed had a deleterious mutation. Twelve mutations were in BRCA1 and three in BRCA2 gene. The mutations and genetic variants were designated according to HUGO recommendations. The gene, mutation, exon, and the details of age of onset and family history are given in Table 1. Six of the 15 pathogenic mutations were novel and have been submitted to the GenBank .
###end p 29
###begin p 30
Gene, exon, mutation description, site of cancer in proband with age of onset and family history
###end p 30
###begin p 31
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
B-Breast cancer, O-ovarian cancer, MA-Maternal aunt, PA-Paternal aunt, MGM-Maternal grandmother, Acc No-GenBank accession number, * - Mutations already reported in our previous publication [18]
###end p 31
###begin p 32
###xml 115 121 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 220 226 220 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 343 349 343 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 352 358 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 435 441 435 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 445 451 445 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 500 506 500 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 559 565 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Apart from the pathogenic mutations, many known missense variations both in the exonic and the intronic regions of BRCA1 and BRCA2 genes were seen in our study. The common missense variations in the exons and introns of BRCA1 and BRCA2 gene are given in Table 2. 85/91 (93%) cases showed at least one variation either in the exon or intron of BRCA1 or BRCA2 gene. Six cases did not show any variations either in exon or intron of both BRCA1 and BRCA2 gene. 28/91 (31%) did not show any variations in BRCA1 and 20/91 (22%) cases did not show any variations in BRCA2 gene.
###end p 32
###begin p 33
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
The missense variations in the exons and the introns (defined polymorphisms in BIC database) of BRCA1 and BRCA2 gene and their percentage
###end p 33
###begin title 34
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
CHEK2*1100delC mutation analysis
###end title 34
###begin p 35
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 613 614 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 846 847 843 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 209 217 <span type="species:ncbi:9606">patients</span>
In our study none of the 91 samples analyzed showed the CHEK2*1100delC mutation. However, two missense mutations were seen in three cases. c.1217G>A; p.R406H which is a known missense mutation was seen in two patients, both with breast cancer and a family history of breast cancer. The second missense variation was c.1175C>T;p.A392V seen in an early onset breast cancer case without any family history of cancer. The Chou Fasman secondary structure prediction showed extension of beta sheet and loss of a turn in the A392V and R406H missense mutation, respectively when compared with the normal sequence (Figure 1). The Swiss model for tertiary structure prediction show marked variation in the structure of A392V missense change. The R406H missense mutation, however did not show any change in its tertiary structure in the Swiss model (Figure 2).
###end p 35
###begin p 36
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Secondary structure as predicted by Chou &#8211; Fasman algorithm</bold>
Secondary structure as predicted by Chou - Fasman algorithm. a) Normal sequence. b) CHEK2 A392V. c) CHEK2 R406H. The missense variations valine and histidine are typed in bold and underlined.
###end p 36
###begin p 37
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Swiss model predicted protein structures of normal, A392V and R406H CHEK2 sequences</bold>
Swiss model predicted protein structures of normal, A392V and R406H CHEK2 sequences.
###end p 37
###begin title 38
IHC analysis, Clinico-Pathological Features and Statistical Analysis
###end title 38
###begin p 39
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 747 755 <span type="species:ncbi:9606">patients</span>
In our study 10/15 BRCA1 mutation positive cases were breast cancer and 2/16 were ovarian cancer cases. 8/10 BRCA1 mutation positive breast cancer cases were ER and PR negative and 5/8 were p53 positive. c-erbB2 data was available for 6 cases, of which 5 were negative and 1 was positive. Of the three BRCA2 mutation positive cases data was available for only one case, which was negative for ER, PR and p53. Clinico-pathological variables like age, stage, grade, histology, ER, PR, c-erbB2 and p53 status for 65 unilateral, 6 bilateral breast cancers and 14 ovarian cancers are given in Table 3. Of the 91 cases, ER, PR, c-erbB2 and p53 data was available only for 59, 57, 50 and 48 cases respectively. Data was not available for 32 cases; 10/32 patients were being managed outside the Institute and either declined or were unable to provide paraffin blocks. In the remaining cases only FNAC was done for the diagnosis of the disease, and not enough slides were available for all the marker study.
###end p 39
###begin p 40
Clinico-pathological characteristics of breast and Ovarian cancer cases
###end p 40
###begin p 41
Statistical analysis between clinico-pathological variables, disease status and prognostic markers revealed association between the stage of the disease at diagnosis and the disease status, which was statistically significant (p < 0.0035). There is a positive association between earlier stage at diagnosis and disease free status. No other variables like grade, age and histological types had significant association with the disease status and the prognostic molecular markers. In addition, no significant association between the mutation status and the clinico-pathological variables were seen.
###end p 41
###begin p 42
###xml 168 176 168 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">logrank </sub>
###xml 209 217 209 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">logrank </sub>
###xml 309 317 309 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">logrank </sub>
###xml 329 337 329 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink">logrank </sub>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
The 5 year overall survival (OS) and disease-free survival (DFS) in breast cancer cases was 75% and 65% and for ovarian cancer cases was 30% and 22% respectively. The Plogrank = 0.30 for overall survival and Plogrank = 0.72 for disease-free survival in breast cancer cases and for ovarian cancer cases it is Plogrank = 0.42 and Plogrank = 0.89 respectively. The Kaplan-Meier curve for the breast and ovarian cancer cases are given in Figure 3 and Figure 4.
###end p 42
###begin p 43
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Kaplan-Meier plot showing Overall survival and Disease free status for Breast cancer cases</bold>
Kaplan-Meier plot showing Overall survival and Disease free status for Breast cancer cases.
###end p 43
###begin p 44
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Kaplan-Meier plot showing Overall survival and Disease free status for Ovarian cancer cases</bold>
Kaplan-Meier plot showing Overall survival and Disease free status for Ovarian cancer cases.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
In our study on 91 patients, 15 pathogenic mutations (16%) in BRCA1 and BRCA2 genes were detected. This is similar to the data from several studies including the study by Wagner et al who had reported 17% mutation in either of the BRCA genes [27-31].
###end p 46
###begin p 47
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 344 350 344 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 405 411 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
There is a four fold greater incidence of BRCA1 mutation (12) compared to BRCA2 (3) mutations in our series of South Indian patients. This is different from the North Indian data wherein almost equal distribution of BRCA1 and BRCA2 mutations was seen in two studies and in the study by Hedau et al [32,33], 4/24 mutations reported, were all in BRCA1 gene [34]. The two South Indian studies have looked at BRCA1 mutations only [35,36].
###end p 47
###begin p 48
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 68 77 68 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">or BRCA2 </italic>
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 246 252 246 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 338 344 338 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 436 442 436 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 709 715 707 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 729 735 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 795 801 793 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 805 811 803 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 881 883 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 981 987 977 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
7/35 HBC families (20%) had mutations in either BRCA1 (5 mutations) or BRCA2 gene (2 mutations). Four of 15, HBOC cases were found to harbor mutations in BRCA1 gene (30%). Zelada-Hedman et al showed that 35% of the HBOC families have mutation in BRCA1 gene, but others report a higher percentage (58% and 43% respectively) of mutation in BRCA1 gene in HBOC families [28,37,38]. The German consortium (2002) study showed 10% mutation in BRCA2 gene in HBOC families [38]. In our series we did not find mutation in BRCA2 gene in HBOC families, which is similar to the results from a study in the Japanese population [39]. Three of 31 early onset (</= 35 years) breast cancer cases had deleterious mutation, 2 in BRCA1 (7%) and 1 in BRCA2 (3%) gene. Peto et al also report 3.5% and 2.4% mutation in BRCA1 and BRCA2 gene, respectively in early onset (</= 35 years) breast cancer cases [40]. Of the three hereditary ovarian cancer families studied, one had a deleterious mutation in the BRCA1 gene.
###end p 48
###begin p 49
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Results published from other Indian groups on BRCA1 &BRCA2 give varying results. Initial studies on smaller sample size gave higher percentage of mutation detected. Saxsena et al reported 2.9% (6/204) mutation with largest sample size so far analyzed [32]. However, this study includes 34 cases with family history and the rest being sporadic cases. The table 4 details the published results from the different groups from India [33-36,41]. The mutation c.68_69delAG; p.Glu23Val fsX16 was seen in four cases (two in HBOC families and two in early onset breast cancer case is the only recurrent mutation seen in this study. The above mentioned mutation has been identified as founder mutation in various populations like the Ashkenazi Jews; however haplotype analysis was not performed in these four families to check for common ancestor [28]. These four families are unrelated and are from different parts of South India, and ethnically different.
###end p 49
###begin p 50
Published results from various Indian groups on BRCA1 and BRCA2 mutation status on hereditary breast and ovarian cancer families or early onset breast cancer cases
###end p 50
###begin p 51
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 192 198 192 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 745 751 745 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 937 943 937 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1002 1008 1002 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 1065 1067 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1068 1070 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1071 1073 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1074 1076 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
Many common missense variants were seen in our series both in the exon and intron of BRCA1 and BRCA2. Most have them been previously reported in other populations. The exonic variants seen in BRCA1 have been reported as unclassified variants in many studies [39,42,43]. In the BIC data base, most of the variants have been classified as having no clinical significance or of unknown clinical significance. Case control studies have shown no difference in the frequencies of these alleles in cases and controls [44]. However, we have not analyzed the frequency of the missense heterozygotes in our control population i.e. unaffected controls with out any family history of breast and/or ovarian cancer. The most common exonic missense variant of BRCA2 gene seen in our cases was N372H. Studies have shown that N372H appears to confer a small increased risk for breast cancer [44]. The missense variants seen in the intronic region of the BRCA1 gene and other less common exonic and intronic variants in BRCA2 have also been previously reported in other populations [28,37,38,40].
###end p 51
###begin p 52
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2*</italic>
###xml 111 117 111 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2*</italic>
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
The CHEK2*1100delC mutation reported in the western populations were also screened for in our cases. Though no CHEK2*1100delC mutation was detected, two missense mutations in the CHEK2 gene (p.R406H and p.A392V) were seen in three cases. The residues, arginine and alanine at positions 406 and 392 are conserved across species. Additionally, the secondary structure prediction using the Chou-Fasman algorithm predicts changes in the secondary structure for both the missense variations [19].
###end p 52
###begin p 53
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 724 730 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 246 251 <span type="species:ncbi:9606">women</span>
###xml 590 597 <span type="species:ncbi:9606">patient</span>
###xml 655 662 <span type="species:ncbi:9606">patient</span>
The Swiss Model software too shows a marked change in the structure for the A392V missense variation, though the R406H did not show a visible change. The variation (R406H) was not seen to be associated with breast cancer cases in French Canadian women [45]. The pathogenicity of the variations can however be confirmed by segregation analysis in other affected family members or other functional studies or screening the normal controls. Two out of the three cases had a family history of breast cancer but we could not get the sample from the other affected family member for testing. The patient with the A392V mutation was an early onset breast cancer patient without any family history. Rest of the coding region of the CHEK2 gene was not screened for mutations.
###end p 53
###begin p 54
###xml 160 162 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 311 317 307 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 408 410 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
In our series, nearly 80% of the breast cancer patients were </= 45 years of age at diagnosis, with 52.7% being </= 35 years at diagnosis, as in other studies [46]. Majority of the breast cancer cases were high-grade tumors (56%). Ho et al reported that 25%-37% of hereditary breast cancers not associated with BRCA1 mutations were ER negative but we found 68% to be negative for ER expression in our study [42]. This correlates well with our hospital statistics in sporadic cancers, wherein 62% of the pre-menopausal patients harbor tumours, which are ER negative.
###end p 54
###begin p 55
###xml 523 528 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 610 615 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
Our study looked at the association between clinico-pathological features, disease status, and prognostic markers. We also looked at the association between the mutation status with disease status and prognostic markers. The stage of the disease at diagnosis and the disease status alone emerged to be statistically significant, wherein a positive association between earlier stage at diagnosis and disease free status was observed. None of the other parameters showed any association. Disease free and overall survival of BRCA mutation positive breast or ovarian cancers did not significantly differ from the BRCA mutation negative cases. Other groups have also not found any survival difference between BRCA mutation positive versus negative cases [46-49].
###end p 55
###begin p 56
Of the 91 cases analyzed, 13 (14%) of the affected probands were issues of consanguineous marriage and had either ovarian cancers (3) or breast cancers (10). Though susceptibility to breast cancer is inhereited as an autosomal dominant trait, modifier genes when present in homozygous state might further increase the risk of cancer.
###end p 56
###begin title 57
Conclusion
###end title 57
###begin p 58
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK</italic>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 150 156 150 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK</italic>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
We have looked at the prevalence of BRCA1, BRCA2 and CHEK1100delC mutation in breast and ovarain caner patients in India. The prevalence of BRCA1 and BRCA2 gene mutaion is similar to other population. CHEK1100delC mutation was not seen our study series. Asoociation between the clinico-pathological variables and mutation status with disease status and prognostic markers revealed significant assocaition between the stage at diagnosis and disease free status alone.
###end p 58
###begin title 59
Competing interests
###end title 59
###begin p 60
The authors declare that they have no competing interests.
###end p 60
###begin title 61
Authors' contributions
###end title 61
###begin p 62
SN, BM and TP carried out the sample collection, PCR-DHPLC, Sequencing, analysis of the data and drafting the article; VS was involved in sample collection, collection and analysis of all the clinical details and drafting of the manuscript; KNN was involved in data analysis and drafting of the article; RS was involved with all the statistical analysis of the data; KRR carried out the immunohistochemistry (IHC) and analysis of the IHC results; UM was involved in the pathological assessment of all the tumour samples; TR designed the study, was involved in the data analysis (clinical and lab), interpretation of the data, drafting the article. All the authors have read and approved the final version of the article.
###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
This study was supported by the Dept. of Biotechnology grant no: BT/PR2649/Med/09/370/2001. The ABI Prism 310 genetic analyzer was a kind donation of Chennai Willingdon Corporate Foundation.
###end p 64
###begin article-title 65
Cancer incidence and mortality in Chennai, India 2003-2005
###end article-title 65
###begin article-title 66
Screening for breast cancer in India - is it an appropriate strategy?
###end article-title 66
###begin article-title 67
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
###end article-title 67
###begin article-title 68
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Identification of the breast cancer susceptibility gene BRCA2
###end article-title 68
###begin article-title 69
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
Low-penetrance susceptibility to breast cancer due to CHEK2 *1100delC in non-carriers of BRCA1or BRCA2 mutations: The CHEK2 breast cancer consortium
###end article-title 69
###begin article-title 70
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies
###end article-title 70
###begin article-title 71
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
###end article-title 71
###begin article-title 72
Clinical Considerations in the Management of Individuals at Risk for Hereditary Breast and Ovarian Cancer
###end article-title 72
###begin article-title 73
Genetic insights into familial cancers-update and recent discoveries
###end article-title 73
###begin article-title 74
Genome-wide association study identifies novel breast cancer susceptibility loci
###end article-title 74
###begin article-title 75
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Multifactorial analysis of differences between sporadic breast cancer and cancers involving BRCA1 and BRCA2 mutation
###end article-title 75
###begin article-title 76
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
Molecular profiles of BRCA1- mutated and matched sporadic breast tumors; relation with clinico-pathological features
###end article-title 76
###begin article-title 77
The pathology of familial breast cancer: morphological aspects
###end article-title 77
###begin article-title 78
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2
###end article-title 78
###begin article-title 79
###xml 50 63 50 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1, BRCA2 </italic>
A Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
###end article-title 79
###begin article-title 80
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
The Role of Estrogens in BRCA1/2 Mutation Carriers
###end article-title 80
###begin article-title 81
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Brca1</italic>
###xml 56 61 <span type="species:ncbi:9606">Women</span>
Clinical And Pathological Features Of Ovarian Cancer In Women With Germ-Line Mutations Of Brca1
###end article-title 81
###begin article-title 82
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1, BRCA2 And CHEK2 </italic>
BRCA1, BRCA2 And CHEK2 (1100 Del C) Germline Mutations In Hereditary Breast And Ovarian Cancer Families In South India
###end article-title 82
###begin article-title 83
FASTA/Hydropathy/Secondary-Structure/Seg
###end article-title 83
###begin article-title 84
SWISS-MODEL: an automated protein homology-modeling server
###end article-title 84
###begin article-title 85
SWISS-MODEL and the Swiss-PdbViewer An environment for comparative protein modelling
###end article-title 85
###begin article-title 86
Protein modeling by E-mail Bio/Technology
###end article-title 86
###begin article-title 87
Estrogen and progesterone receptor determinations in breast cancer technology and biology
###end article-title 87
###begin article-title 88
Expression of c-ErbB2, Cyclin D1 and ER and their clinical implications in Invasive ductal carcinoma of breast
###end article-title 88
###begin article-title 89
###xml 47 52 <span type="species:ncbi:9606">human</span>
Expression of c-ErbB2 protooncogene protein in human breast cancer. Recent results
###end article-title 89
###begin article-title 90
Influence of Tp53 gene alterations and c-erbB2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
###end article-title 90
###begin article-title 91
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations
###end article-title 91
###begin article-title 92
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
BRCA1 - related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics
###end article-title 92
###begin article-title 93
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 94 99 <span type="species:ncbi:9606">Women</span>
Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer
###end article-title 93
###begin article-title 94
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
BRCA1 and BRCA2 Germline mutations in Sardinian breast cancer families and their implications for genetic counseling
###end article-title 94
###begin article-title 95
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Evaluation of BRCA1 and BRCA2 mutation and risk prediction models in Asian country (Malaysia) with a relatively low incidence of breast cancer
###end article-title 95
###begin article-title 96
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India
###end article-title 96
###begin article-title 97
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families
###end article-title 97
###begin article-title 98
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
BRCA1 and BRCA2 in Indian breast cancer patients
###end article-title 98
###begin article-title 99
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Novel germline mutations in breast cancer susceptibility genes BRCA 1, BRCA2 and p53 gene in breast cancer patients from India
###end article-title 99
###begin article-title 100
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families
###end article-title 100
###begin article-title 101
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
A screening for BRCA1 mutations in breast and breast-ovarian cancer families from Stockholm region
###end article-title 101
###begin article-title 102
###xml 90 98 <span type="species:ncbi:9606">patients</span>
German consortium for hereditary breast and ovarian cancer: Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population
###end article-title 102
###begin article-title 103
Fequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families
###end article-title 103
###begin article-title 104
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Prevalance of BRCA1 and BRCA2 gene Mutations in patients with early-onset breast cancer
###end article-title 104
###begin article-title 105
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer
###end article-title 105
###begin article-title 106
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
###xml 44 49 <span type="species:ncbi:9606">women</span>
Novel germline BRCA 1 mutations detected in women in Singapore who developed breast carcinoma before the age of 36 years
###end article-title 106
###begin article-title 107
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA </italic>
Conformation of BRCA 1 by analysis of germline mutations linked to breast and ovarian cancer in ten families
###end article-title 107
###begin article-title 108
"Other" breast caner susceptibility genes searching for more holy grail
###end article-title 108
###begin article-title 109
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 123 128 <span type="species:ncbi:9606">Women</span>
Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian Women
###end article-title 109
###begin article-title 110
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Survival and tumor characteristics of breast cancer patients with germline mutations of BRCA1
###end article-title 110
###begin article-title 111
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Swden
###end article-title 111
###begin article-title 112
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers
###end article-title 112
###begin article-title 113
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA</italic>
###xml 39 44 <span type="species:ncbi:9606">women</span>
BRCA-aasociated breast cancer in young women
###end article-title 113

